Forasartan
chemical compound
Forasartan, otherwise known as the compound SC-52458, is a nonpeptide angiotensin II receptor antagonist (ARB, AT1 receptor blocker).
Indications
Forasartan is indicated for the treatment of hypertension and, similar to other ARBs, it protects the kidneys from kidney blood vessel damage caused by increased kidney blood pressure by blocking renin–angiotensin system activation.
Administration
Forasartan is administered in the active oral form which means that it must go through first pass metabolism in the liver. The dose administered ranges between 150 mg-200 mg daily. Increasing to more than 200 mg daily does not offer significantly greater AT1 receptor inhibition. Forasartan is absorbed quickly in the GI, and within an hour it becomes significantly biologically active. Peak plasma concentrations of the drug are reached within one hour.
Contraindications
Negative side effects of Forasartan are similar to other ARBs, and include hypotension and hyperkalemia. There are no drug interactions identified with forasartan.
Pharmacology
The angiotensin II receptor, type 1
Angiotensin II binds to AT1 receptors, increases contraction of vascular smooth muscle, and stimulates aldosterone resulting in sodium reabsorption and increase in blood volume.
The public source identifies “Forasartan” as chemical compound. This brief keeps that definition visible, then builds a research path around Forasartan, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Forasartan”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Dec 21, 2025. The linked authority identifier is Q8564451. None of the 0 selected statements returned an explicit reference.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Forasartan”, its source revision and the description used here.
- Expand the search: follow Forasartan primary sources, Forasartan archive and Forasartan research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Forasartan”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Forasartan” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.